PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33670955-0	2021	Oral Proteasomal Inhibitors Ixazomib, Oprozomib, and Delanzomib Upregulate the Function of Organic Anion Transporter 3 (OAT3): Implications in OAT3-Mediated Drug-Drug Interactions.	ixazomib	28-36	solute carrier family 22 member 8	Homo sapiens	91-118	
33670955-0	2021	Oral Proteasomal Inhibitors Ixazomib, Oprozomib, and Delanzomib Upregulate the Function of Organic Anion Transporter 3 (OAT3): Implications in OAT3-Mediated Drug-Drug Interactions.	ixazomib	28-36	solute carrier family 22 member 8	Homo sapiens	120-124	
33670955-0	2021	Oral Proteasomal Inhibitors Ixazomib, Oprozomib, and Delanzomib Upregulate the Function of Organic Anion Transporter 3 (OAT3): Implications in OAT3-Mediated Drug-Drug Interactions.	ixazomib	28-36	solute carrier family 22 member 8	Homo sapiens	143-147	
33670955-4	2021	Therefore, this study investigated the effects of ixazomib, oprozomib, and delanzomib on the expression and transport activity of OAT3 and elucidated the underlying mechanisms.	ixazomib	50-58	solute carrier family 22 member 8	Homo sapiens	130-134	
33670955-7	2021	Together, our study discovered a novel role of anticancer agents ixazomib, oprozomib, and delanzomib in upregulating OAT3 function, unveiled the proteasome as a promising target for OAT3 regulation, and provided implication of OAT3-mediated drug-drug interactions, which should be warned against during combination therapies with proteasome inhibitor drugs.	ixazomib	65-73	solute carrier family 22 member 8	Homo sapiens	117-121	
33670955-7	2021	Together, our study discovered a novel role of anticancer agents ixazomib, oprozomib, and delanzomib in upregulating OAT3 function, unveiled the proteasome as a promising target for OAT3 regulation, and provided implication of OAT3-mediated drug-drug interactions, which should be warned against during combination therapies with proteasome inhibitor drugs.	ixazomib	65-73	solute carrier family 22 member 8	Homo sapiens	182-186	
33670955-7	2021	Together, our study discovered a novel role of anticancer agents ixazomib, oprozomib, and delanzomib in upregulating OAT3 function, unveiled the proteasome as a promising target for OAT3 regulation, and provided implication of OAT3-mediated drug-drug interactions, which should be warned against during combination therapies with proteasome inhibitor drugs.	ixazomib	65-73	solute carrier family 22 member 8	Homo sapiens	182-186